Italy

Goldman Sachs Alternatives acquires control of Italian medtech firm Numantec.

[Exhibition] CPhI Europe 2026 — /exhibit

[Exhibition] CPhI Europe 2026 — /exhibit

The IN.PACT AV Access trial shows DCB is superior for vascular access stenosis treatment, improving patient outcomes.

The Axess graft shows 100% patency and safety in early human trials, promising for dialysis patients.

Italy's WISE secured $34.8 million in Series D funding for spinal cord stimulator development.

[Exhibition] CPhI Europe 2026 — /digital-products/pharma-marketing-toolkit/pharma-marketing-toolkit-form/

[Exhibition] CPhI Europe 2026 — /digital-products/pharma-marketing-toolkit/pharma-marketing-toolkit-form/pharma-marketing-toolkit-typ/

Xeltis reported 12-month aXess conduit trial results showing 100% secondary patency and 0% infections in 20 patients.

Cardionovum's Aperto DCB shows high effectiveness in prolonging dialysis access survival with 80% patency rate.

UChicago's Milner calls for RCTs on EVAR and complex AAA repairs, highlighting Medtronic's ongoing trials.

Cordis completed patient enrolment in the RADIANCY study for the S.M.A.R.T. Radianz stent system in Europe.